{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:24:52Z","timestamp":1774679092261,"version":"3.50.1"},"reference-count":40,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7883\/yoken.jjid.2025.104","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:09:32Z","timestamp":1753913372000},"page":"65-71","source":"Crossref","is-referenced-by-count":0,"title":["Sociodemographic and Clinical Correlates of Markers of Immune Activation, Exhaustion and Platelet Activation among HIV-Infected Patients Initiating Antiretroviral Therapy in Dar es Salaam, Tanzania"],"prefix":"10.7883","volume":"79","author":[{"given":"Tosi Michael","family":"Mwakyandile","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Ambrose","family":"Shayo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Galula","family":"Sasi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand Mukama","family":"Mugusi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey","family":"Barabona","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Japan"},{"name":"Department of Microbiology and Immunology, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eligius Francis","family":"Lyamuya","sequence":"additional","affiliation":[{"name":"Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Japan"},{"name":"Department of Microbiology and Immunology, School of Biomedical Sciences, Campus College of Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lucas S, Nelson AM. HIV and the spectrum of human disease. J Pathol. 2015;235:229-241.","DOI":"10.1002\/path.4449"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248-1259.","DOI":"10.1093\/infdis\/jiu254"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. So-Armah KA, Tate JP, Chang CCH, et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV Infected and Uninfected People? J Acquir Immune Defic Syndr (1999). 2016;72:206-213.","DOI":"10.1097\/QAI.0000000000000954"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV Infection. J Infect Dis. 2009;200:973-983.","DOI":"10.1086\/605447"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fahey JL, Taylor JMG, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581-1590.","DOI":"10.1097\/00002030-199813000-00004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lv T, Cao W, Li T. HIV-related immune activation and inflammation: current understanding and strategies. J Immunol Res. 2021; 2021:7316456.","DOI":"10.1155\/2021\/7316456"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hattab S, Guiguet M, Carcelain G, et al. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. HIV Med. 2015;16:553-562.","DOI":"10.1111\/hiv.12257"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.","DOI":"10.1086\/374786"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Younas M, Psomas C, Reynes J, et al. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89-105.","DOI":"10.1111\/hiv.12310"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Giorgi JV., Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870.","DOI":"10.1086\/314660"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Streeck H, Maestri A, Habermann D, et al. Dissecting drivers of immune activation in chronic HIV-1 infection. EBioMedicine. 2022;83:104182.","DOI":"10.1016\/j.ebiom.2022.104182"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Deeks SG, Kitchen CMR, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947.","DOI":"10.1182\/blood-2003-09-3333"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kamat A, Misra V, Cassol E, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One. 2012;7:e30881.","DOI":"10.1371\/journal.pone.0030881"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bastard JP, Fellahi S, Couffignal C, et al. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. J Antimicrob Chemother. 2015;70:1816-1824.","DOI":"10.1093\/jac\/dkv036"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borges \u00c1H, O\u2019Connor JL, Phillips AN, et al. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014;9:e90978.","DOI":"10.1371\/journal.pone.0090978"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-136.","DOI":"10.1093\/cid\/cis406"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Utay NS, Hunt PW. Role of immune activation in progression to AIDS. Curr Opin HIV AIDS. 2016;11:131-137.","DOI":"10.1097\/COH.0000000000000242"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. O\u2019Brien M, Montenont E, Hu L, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr. 2013;63:280-288.","DOI":"10.1097\/QAI.0b013e31828a292c"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation.2001;103:491-495.","DOI":"10.1161\/01.CIR.103.4.491"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Scialla JJ, Plantinga LC, Kao WHL, et al. Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients. Am J Nephrol. 2011;33:224-230.","DOI":"10.1159\/000324517"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24:2166-2179.","DOI":"10.1016\/j.ehj.2003.08.021"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nkambule BB, Mxinwa V, Mkandla Z, et al. Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis. BMC Med. 2020;18:357.","DOI":"10.1186\/s12916-020-01801-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mesquita EC, Hottz ED, Amancio RT, et al. Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. Sci Rep. 2018;8:14999.","DOI":"10.1038\/s41598-018-33403-0"},{"key":"24","unstructured":"24. UNAIDS. The path that ends AIDS: UNAIDS global AIDS update 2023. Geneva: JointUnited Nations Programme on HIV\/AIDS; 2023."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mwakyandile T, Shayo G, Mugusi S, et al. Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial. BMJ Open. 2021;11:e049330.","DOI":"10.1136\/bmjopen-2021-049330"},{"key":"26","unstructured":"26. BD Cytometric Bead Array (CBA) Human Soluble Protein Master Buffer Kit Instruction Manual; BD Cytometric Bead Array (CBA) Human Soluble Protein Master Buffer Kit Instruction Manual. 2019."},{"key":"27","unstructured":"27. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Vol. 3, IFAC Proceedings Volumes (IFAC-PapersOnline). 2013."},{"key":"28","unstructured":"28. World Health Organization. Non-communicable diseases. Fact sheets. 16 September 2023. Available at <https:\/\/www.knowledge-action-portal.com\/en\/content\/noncommunicable-diseases>. Accessed January 28, 2026."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Asher I, Guri KM, Elbirt D, et al. Characteristics and outcome of patients diagnosed with HIV at older age. Medicine (Baltimore). 2016;95:e2327.","DOI":"10.1097\/MD.0000000000002327"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Eduardo E, Lamb MR, Kandula S, et al. Characteristics and outcomes among older HIV-positive adults enrolled in HIV programs in four sub-Saharan African countries. PLoS One. 2014;9:e103864.","DOI":"10.1371\/journal.pone.0103864"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Appay V, Fastenackels S, Katlama C, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011;25:1813-1822.","DOI":"10.1097\/QAD.0b013e32834640e6"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319-329.","DOI":"10.1016\/j.arr.2010.11.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Deeks SG. HIV Infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155.","DOI":"10.1146\/annurev-med-042909-093756"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Gunda DW, Godfrey KG, Kilonzo SB, et al. Cytopenias among ART-naive patients with advanced HIV disease on enrolment to care and treatment services at a tertiary hospital in Tanzania: a cross-sectional study. Malawi Med J. 2017;29:43-52.","DOI":"10.4314\/mmj.v29i1.9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Njelekela M, Muhihi A, Aveika A, et al. Prevalence of hypertension and its associated risk factors among 34,111 HAART na\u00efve HIV-infected adults in Dar es Salaam, Tanzania. Int J Hypertens. 2016;2016:5958382.","DOI":"10.1155\/2016\/5958382"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8 + T-cell activation on CD4 + T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123-2131.","DOI":"10.1097\/QAD.0b013e32834c4ac1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Eggena MP, Barugahare B, Okello M, et al. T Cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4 + T cell depletion, and coinfection. J Infect Dis. 2005;191:694-701.","DOI":"10.1086\/427516"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr. 2012;59:340-346.","DOI":"10.1097\/QAI.0b013e3182439355"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Nkambule BB, Davison GM, Ipp H. The evaluation of platelet function in HIV infected, asymptomatic treatment-na\u00efve individuals using flow cytometry. Thromb Res. 2015;135:1131-1139.","DOI":"10.1016\/j.thromres.2015.01.031"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Nkambule BB, Davison G, Ipp H. The value of flow cytometry in the measurement of platelet activation and aggregation in human immunodeficiency virus infection. Platelets. 2015;26:250-257.","DOI":"10.3109\/09537104.2014.909021"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/79\/2\/79_JJID.2025.104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:59:45Z","timestamp":1774670385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/79\/2\/79_JJID.2025.104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2025.104","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"JJID.2025.104"}}